4,962 Shares in Medpace Holdings, Inc. $MEDP Acquired by Trek Financial LLC

Trek Financial LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,962 shares of the company’s stock, valued at approximately $2,551,000.

Several other large investors have also recently added to or reduced their stakes in MEDP. Baillie Gifford & Co. boosted its holdings in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after acquiring an additional 62,503 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its position in Medpace by 14.8% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 55,861 shares of the company’s stock valued at $28,721,000 after purchasing an additional 7,194 shares during the last quarter. Palisades Investment Partners LLC boosted its stake in Medpace by 0.9% during the 3rd quarter. Palisades Investment Partners LLC now owns 15,892 shares of the company’s stock valued at $8,171,000 after purchasing an additional 135 shares during the period. Bailard Inc. bought a new position in Medpace in the 3rd quarter worth about $231,000. Finally, Stock Yards Bank & Trust Co. bought a new position in Medpace in the 3rd quarter worth about $241,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MEDP shares. Barclays boosted their price objective on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. TD Cowen reissued a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Finally, Mizuho set a $660.00 target price on shares of Medpace in a research report on Friday, January 9th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Stock Performance

MEDP opened at $588.05 on Friday. The company has a market capitalization of $16.57 billion, a PE ratio of 41.12, a P/E/G ratio of 1.97 and a beta of 1.43. The stock’s fifty day moving average is $583.65 and its 200-day moving average is $521.26. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same period in the prior year, the company earned $3.01 EPS. Medpace’s revenue was up 23.7% on a year-over-year basis. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Medpace news, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the transaction, the chief financial officer owned 6,000 shares of the company’s stock, valued at approximately $3,542,100. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 387,925 shares of company stock worth $233,386,647 in the last ninety days. 20.30% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.